Biodecoding: effective method as a preventive treatment of migraine in women
DOI:
https://doi.org/10.62486/agsalud2025191Keywords:
migraine, Biodecoding, preventive treatmentAbstract
Introduction: Migraine is a common neurological disease. Its preventive treatment has a low adherence rate due to the adverse reaction caused by the drugs. For this reason, it is important to demonstrate the effectiveness of a comprehensive and holistic method such as Biodecoding.
Aim: determine the efficacy of Biodecoding as preventive treatment of migraine in women.
Methods: an experimental research was designed, pretest-postest and with a control group at the Dr. Miguel Enriquez Clinical Surgical Teaching Hospital in Havana, between November 2023 and April 2024. 40 patients were included in the study,20 who received treatment only with gabapentin (control group) and 20 who were additionally treated with biodecoding ( study group). The response was evaluated one month and three months after the intervention. Descriptive statistics and inferences were used to analyze the data.
Results: in both groups after the intervention, a decrease in the frecuency, intensity and duration of migraine was observed, however this decrease was greater in the study group.
Conclusions: It was conclude that Biodecoding is an effective method in the preventive treatment of migraine in women
References
1. Garzón-Cutiño L, Valdés-Santiago D, Pérez-Esquivel L, Olivera-Vega M, Valdés-Izquierdo L. Utilidad de la Biodescodificación en el tratamiento de las diferentes enfermedades. AG Salud. [Internet]. 2024; 2:7. Disponible en: https://doi.org/10.62486/agsalud202472.
2. Valdés-Izquierdo L. Enseñanza de la integración emocional en la asignatura propedéutica clínica y semiología médica [Tesis doctorado en Educación Médica]. La Habana: Universidad de Ciencias Médicas de La Habana; 2023.
3. Guillén L, Alcántara K. Del síntoma a la biodescodificación de la enfermedad desde la psicoterapia Gestalt. Revista de Divulgación Científica. [Internet]. 2019; 2(002):32. Disponible en: http://ugestalt.edu.mx/reveles/vol2/No_2.pdf.
4. Navarro-Pérez MP, Marín-García M, Bellosta-Diago E, Santos–Lasaosa. Epidemiología de la migraña en España y Latinoamérica. Revista Neurología. [Internet]. 2020; 71:110-118. Disponible en: http://doi.org/10.33588/rn.7103.2019266.
5. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Ozge A et al. Migraine: epidemiology and systems of care. Lancet. [Internet]. 2021; 397 (1283):1485-1495. http://doi.org/10.1016/SO140-6736(2032160-7.
6. Santos-Lasaosa S, Belvis R, Cuadrado ML, Díaz-Insa S, Gago-Veiga AB, Guerrero-Peral AL, Huerta M, Irimia P, Láinez JM, Latorre G, Leira R, Pascual J, Porta-Etessam J, Sánchez del Río M, Viguera J, Pozo-Rosich P. CGRP en migraña: de la fisiopatología a la terapéutica. Neurología. [Internet]. 2022; 37(5). Disponible en: https://doi.org/10.1016/j.nrl.2019.03.013.
7. Solano-Mora A, Ramírez-Vargas X, Solano-Castillo A. Actualización de la Migraña. Revista Médica Sinergia. [Internet]. 2020; 5(4):e447. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=7398772.
8. Aguilar- Shea AL, Membrilla JA, Díaz de Terán J. Migrain review for general practice. Atención Primaria. [Internet]. 2022; 54(2):102208. Disponible en: https://doi.org/10.1016/j.aprim.2021.02208.
9. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Academic Emergency Medicine. [Internet]. 2001; 8(12):1153-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11733293/.
10. Lipton RB, Pozo-Rosich P, Blumenfeld AM, Li Y, Severt L, Stokes JT et al.Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial. Neurology. [Internet]. 2023; 21; 100(8): e764–e777. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984220/.
11. Croop R, Lipton R, Thiry A, Kamen L, Goadsby P. A phase 2/3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rimegepant for the preventive treatment of migraine. Neurology. [Internet]. 2021; 96:15. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33338437/.
12. Zain S, Khan M, Alam R, Zafar I, Ahmed S. Comparison of efficacy and safety of topiramate with gabapentin in migraine prophylaxis: randomized open label control trial. JPMA. The Journal of the Pakistan Medical Association. [Internet]. 2013; 63(1):3-7. Disponible en: https://www.semanticscholar.org/paper/Comparison-of-efficacy-and-safety-of-topiramate-in-Zain-han/59b22bb1d2d01498d8a12d91a772cafbaf831bfa.
13. Prieto-Peres MF, Peres-Mercante JP, Belitardo-de-Olivera A. Non-Pharmacological Treatment for Primary Headaches Prevention and Lifestyle Changes in a Low-Income Community of Brazil: A Randomized Clinical Trial I. Headache. [Internet]. 2019; 59(1):86-96. Disponible en: https://doi.org/10.1111/head.13457.
14. Villa FT, Domínguez V, Henao LM, Taborda SA, Giraldo YM. Characteristics of chronic migraine after a pericraneal block with local anesthetics and dexamethasone in adults. Neurología, Neurocirugía y Psiquiatría. [Internet]. 2022; 50(2):44-50. Disponible en: https://www.medigraphic.com/pdfs/revneuneupsi/nnp-2022/nnp222b.pdf.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Lisbel Garzón Cutiño, Libertad Engracia Valdés Izquierdo, Damian Valdés Santiago (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
